Biotech Daily

Daily news on ASX-listed biotechnology companies

Biotech Daily covers the major announcements from more than 140 ASX-listed biotech companies as well as research institutes and developments in government policy.

Published shortly after the stock market closes five days a week - excluding public holidays - Biotech Daily is the only comprehensive daily source of information on the listed biotechnology sector.

The Biotech Daily Top 40 Index (BDI-40) is selected on the basis of interesting technologies, benefit to human health and investment potential. Market capitalization is important, but is not a sole arbiter.

2024 base-rate subscriptions are $A2,050 a year (including GST in Australia).

Subscribers include biotech directors and CEOs, major pharmaceutical companies, universities, research institutes, investment houses, market analysts, retail investors, doctors, medical specialists and hospital management.

Subscribe to receive the latest news from Biotech Daily

August BDI-40 Slips 1.5%; ASX200 Flat; Big Caps Up 0.3%; NBI Up 1%

Monday September 2, 2024

The last month of Australian Winter – with Melbourne in full Spring bloom – was mixed, with the August Biotech Daily Top 40 Index (BDI-40) down 1.5 percent after nine months of consecutive gains.

The benchmark ASX200 was even at 8,092 points, the Nasdaq Biotechnology Index (NBI) was up 0.8 percent; the collective value of the three Big Caps of Cochlear, CSL and Resmed (which are not included in the BDI-40) edged up 0.3 percent to its highest value on record at $220,711 million, while Cannabis Corner continued to fall, down 0.75 percent.

Resmed’s $4,756 million, or 10.0 percent rise to $52,484 million, just compensated for CSL’s 0.6 percent fall to $148,808 million and Cochlear’s 14.1 percent loss to $19,419 million, following three consecutive months of gains.

For the year to August 31, the BDI-40 was up 69.0 percent, the NBI improved 18.6 percent, the three Big Caps were up 17.9 percent and the ASX200 rose 10.8 percent.

In August, 17 of the BDI-40 companies were up, eight by more than 10 percent; 21 fell, with 13 down by more than 10 percent, and two were unchanged.

Again, Pro Medicus added the most - $364 million in August - but Amplia was the percentage best, up $18 million or 120 percent to $33 million, followed by Opthea (36.1%), Medical Developments (27.8%), Percheron (20.0%), Immutep (17.4%), Resonance (16.0%), Clarity (14.9%) and Imugene (11.3%).

Last month’s 50 percent best, Atomo, led the August falls, down $11 million or 45.8 percent to $13 million, followed by Actinogen (36.8%), Impedimed (22.4%), Cynata (22.2%), Micro-X (22.2%), Neuren (21.2%), Aroa (13.4%), Avita (12.5%), Cyclopharm (12.1%), Medadvisor (11.9%), Polynovo (11.5%), Nova Eye (11.1%) and Curvebeam (10.7%).

The 12 companies that comprise Cannabis Corner slipped a collective 0.75 percent in August to $265 million – a very long way from the $1.9 billion peak in 2021 – and down 45.1 percent for the year to August 31, 2024. Bioxyne improved 91.7 percent to $23 million, Emyria fell 23.5 percent to $13 million, three were unchanged and the rest had small falls or rises.

Outside the BDI-40, several companies in the Third 20, were knocking on the BDI-40 door; including Argenica, Bcal, Botanix and EBR, with Control Bionics, Oncosil and Radiopharm in recovery.

LTR had a 268.6 percent bump from $65 million to a market capitalization of $159 million, following news that its vardenafil-based (Levitra) Spontan nasal spray for erectile dysfunction had Australian Therapeutic Goods Administration special access scheme and authorised prescriber approvals.

On the Nasdaq, Kazia recovered 11.8 percent to $19 million, but Bionomics, Eyepoint (Psivida), Incannex and Redhill (with Australian assets) all fell. Queensland’s Protagonist added $277 million or 8.0 percent to $3,735 million. 

BDI-40 v S&P ASX200 Jun 30, 2006 to Aug 31, 2024

5-Year Big Caps (Cochlear, CSL, Resmed) to Aug 31, 2024

BDI-40 ($m) v S&P ASX200 – Jan 31, 2020 - Aug 31, 2024
(pre-Covid to date)

Biotech Daily Top 40 With Market Capitalization At August 31, 2024

Biotech Daily editor, David Langsam, owns shares in 4D Medical, Acrux, Actinogen, Alcidion, Alterity, Amplia, BTC Health, Clarity, Cochlear, Control Bionics, Cynata, Nanosonics, Neuren, Patrys, Polynovo, Syntara and Telix, as well as non-biotechnology stocks.

Through Australian Ethical Superannuation he has an indirect interest in a range of biotechnology companies.

These holdings are liable to change:
https://www.australianethical.com.au/personal/ethical-investing/companies-we-invest-in/

TOP